Is GILD Worth Buying in 2026?

Gilead Sciences Inc

STOCK BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) Updated 2026-07-26

Here’s whether Gilead Sciences Inc (GILD) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Caution.

🟡
Caution

Positives: RSI 50 — healthy momentum range; strong 1-year return of +14.2%. Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-0.15% over 10 days). Currently 17.8% off its 52-week high. Score: -2/7.

Ready to act on this? 📈 Trade on Webull

GILD is trading below its 200-day MA ($131.41) — a key warning sign the longer-term trend is under pressure. An RSI of 49.5 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +14.2% compares to +16.5% for SPY (trailed the market by 2.2%).

$10,000 invested 1 year ago → $11,423 today
vs. S&P 500 (SPY) — same period trailed market by 2.2%

1-Year Price Chart

Daily candles
MA-50 MA-200 Up Down

Signal Check

Above 200-day MA ($131.41)
Above 50-day MA ($129.65)
RSI(14) neutral zone (30–70) — currently 49.5
Positive return (+14.2%)
!Within 10% of period high (−17.8%)
Period Range $129.31
$108.46 $157.29
RSI (14) 49.5
0 · OversoldOverbought · 100

Key Metrics

Price$129.31
Period Return+14.2%
Period High$157.29
Period Low$108.46
Drawdown−17.8%
MA-50$129.65
MA-200$131.41
RSI (14)49.5
Avg Volume (30d)7.7M
vs. SPYtrailed by 2.2%
Return Rank#411 of 999

Trade GILD

📈 Trade on Webull 📊 Trade on moomoo 💹 Interactive Brokers